Immune checkpoint inhibitors (ICIs) have been approved as first-line therapy for advanced non-small cell lung cancer (NSCLC). The probiotic MIYAIRI 588 can potentially improve the outcomes of patients with advanced NSCLC treated...
Read More
The following is a summary of “Determinants of successful minimally invasive surgery (MIS) for...
Read MorePatients with non-small cell lung cancer (NSCLC) with liver metastasis have a poor prognosis, and there are no reliable biomarkers for predicting disease progression. Currently, no recognized and reliable prediction model exists...
Read More
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No...
Read MoreNon-small cell lung cancer (NSCLC) patients with EGFR mutations exhibit an unfavorable response to immune checkpoint inhibitor (ICI) monotherapy, and their tumor microenvironment (TME) is usually immunosuppressed. TGF-β plays an...
Read More
Click to read the study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may...
Read More
1. Treatment with osimertinib significantly improved progression-free survival, compared to...
Read MoreLung cancer is still the leading cause of cancer-related mortality. Over the past two decades, the management of non-small cell lung cancer (NSCLC) has undergone a significant revolution. Since the first identification of...
Read More
MONDAY, April 22, 2024 (HealthDay News) — The U.S. Food and Drug Administration has approved...
Read More
To describe the clinical characteristics of patients with non-small cell lung cancer (NSCLC) who developed checkpoint inhibitor pneumonitis (CIP) and to explore potential prognostic factors. NSCLC patients who were complicated...
Read MoreThere are differences in the pharmacoeconomics of Immune checkpoint blocking (ICB) therapies for the treatment of lung squamous cell carcinoma (LSCC). However, no corresponding review studies have fully discussed the...
Read MoreTo analyze the efficacy of stereotactic ablative brachytherapy (SABT) and percutaneous microwave ablation (MWA) for the treatment of early-stage non-small cell lung cancer (NSCLC).Patients with early-stage (T1-T2aN0M0) NSCLC who...
Read More
1. Median progression-free survival was greater in the SBRT group than in the standard-of-care...
Read More
1. Median progression-free survival was greater in the SBRT group than in the standard-of-care...
Read MoreThe metastasis of non-small cell lung cancer (NSCLC) is the leading death cause of NSCLC patients, which requires new biomarkers for precise diagnosis and treatment. Circular RNAs (circRNAs), the novel noncoding RNA, participate...
Read More
The following is a summary of “Impact of Concurrent Genomic Alterations on Clinical Outcomes in...
Read MoreAstragaloside IV (AS-IV) has been shown to have a curative effect on non-small cell lung cancer (NSCLC). This study aimed to elucidate the role of AS-IV in NSCLC cell anlotinib resistance (AR).The NSCLC/AR cells, resistant to...
Read More
1. While perceived appetite did not differ between study groups, patients receiving mirtazapine...
Read MoreIruplinalkib (WX-0593) is a new-generation, potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) and has shown systemic and central nervous system (CNS) efficacy in ALK-positive non-small-cell lung cancer...
Read MoreSurgical resection is the most effective therapeutic option for the cure in early stage resectable non-small-cell lung cancer (NSCLC). However, despite complete resection, up to 70% of patients die within 5 years mainly due to...
Read More
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
